Congenital fibrinogen disorders: An update

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 6, 2013, Pages 585-595

  De Moerloose, Philippe ^a   Casini, Alessandro ^b   Neerman Arbez, Marguerite ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

afibrinogenemia; bleeding disorder; dysfibrinogenemia; fibrinogen; hypofibrinogenemia; thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 8; COMPLEMENTARY DNA; ESTROGEN; FIBRINOGEN; GESTAGEN; IRON; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; VON WILLEBRAND FACTOR;

AFIBRINOGENEMIA; ALTERNATIVE RNA SPLICING; AMINO ACID SUBSTITUTION; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BLEEDING DISORDER; BLEEDING TIME; BLOOD CLOTTING TEST; BRAIN HEMORRHAGE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL FEATURE; COMPRESSION STOCKING; CONSANGUINEOUS MARRIAGE; CREUTZFELDT JAKOB DISEASE; CROSS LINKING; CRYOPRECIPITATE; DELAYED HYPERSENSITIVITY; DIAGNOSTIC ERROR; DYSFIBRINOGENEMIA; ENDOPLASMIC RETICULUM; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL AMYLOIDOSIS; FIBRINOGEN DEFECT; FIBRINOGEN SYNTHESIS; FRAMESHIFT MUTATION; GENE CLUSTER; GENE FREQUENCY; GENE THERAPY; GENETIC ANALYSIS; GENOTYPE; HEMARTHROSIS; HEMOPHILIA; HEMOSTASIS; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYPOFIBRINOGENEMIA; IRON DEFICIENCY ANEMIA; KIDNEY AMYLOIDOSIS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MENORRHAGIA; MISSENSE MUTATION; NONSENSE MUTATION; ONSET AGE; PARTIAL THROMBOPLASTIN TIME; POSTPARTUM HEMORRHAGE; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT ABORTION; SCREENING TEST; SKIN TEST; SPONTANEOUS ABORTION; SUBSTITUTION THERAPY; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; TRANSLATION INITIATION;

AFIBRINOGENEMIA; ANIMALS; FIBRINOGEN; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEMORRHAGE; HUMANS; MUTATION; THROMBOSIS;

EID: 84883246103     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1349222     Document Type: Article

References (96)

1. Blombäck M., Blombäck B., Mammen E. F., Prasad A. S. Fibrinogen Detroit-a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature: 1968; 218 5137 134 137
2. Neerman-Arbez M., Honsberger A., Antonarakis S. E., Morris M. A. Deletion of the fibrinogen [correction of fibrogen] alpha-chain gene (FGA) causes congenital afibrogenemia. J Clin Invest: 1999; 103 2 215 218
3. de Moerloose P., Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost: 2009; 35 4 356 366
4. Neerman-Arbez M., de Moerloose P. Hereditary fibrinogen abnormalities. In: Kaushansky K., Lichtman M., Beutler E., et al, eds. Williams Hematology. 8th ed. New York, NY McGraw-Hil: 2010; 1 33
5. Galanakis D. Afibrinogenemias and dysfibrinogenemias. In: Marder V., White G. C., Aird W. C., eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Philadelphia, PA Lippincott Williams & Wilkins: 2012; 693 708
6. Mosesson M. W. Fibrinogen and fibrin structure and functions. J Thromb Haemost: 2005; 3 8 1894 1904
7. Tennent G. A., Brennan S. O., Stangou A. J., O'Grady J., Hawkins P. N., Pepys M. B. Human plasma fibrinogen is synthesized in the liver. Blood: 2007; 109 5 1971 1974
8. Medved L., Weisel J. W. Fibrinogen and Factor XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost: 2009; 7 2 355 359
9. Kant J. A., Fornace A. J. Jr, Saxe D., Simon M. I., McBride O. W., Crabtree G. R. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A: 1985; 82 8 2344 2348
10. de Maat M. P., Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol: 2005; 12 5 377 383
11. Huang S., Mulvihill E. R., Farrell D. H., Chung D. W., Davie E. W. Biosynthesis of human fibrinogen. Subunit interactions and potential intermediates in the assembly. J Biol Chem: 1993; 268 12 8919 8926
12. Henschen-Edman A. H. On the identification of beneficial and detrimental molecular forms of fibrinogen. Haemostasis: 1999; 29 2-3 179 186
13. Collen D., Tytgat G. N., Claeys H., Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol: 1972; 22 6 681 700
14. Handagama P., Scarborough R. M., Shuman M. A., Bainton D. F. Endocytosis of fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa). Blood: 1993; 82 1 135 138
15. Mosesson M. W., Siebenlist K. R., Meh D. A. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci: 2001; 936 11 30
16. Weisel J. W. Fibrinogen and fibrin. Adv Protein Chem: 2005; 70 247 299
17. Fenton J. W. II, Olson T. A., Zabinski M. P., Wilner G. D. Anion-binding exosite of human alpha-thrombin and fibrin(ogen) recognition. Biochemistry: 1988; 27 18 7106 7112
18. Mosesson M. W. Update on antithrombin I (fibrin). Thromb Haemost: 2007; 98 1 105 108
19. Uitte de Willige S., de Visser M. C., Houwing-Duistermaat J. J., Rosendaal F. R., Vos H. L., Bertina R. M. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood: 2005; 106 13 4176 4183
20. Rabe F., Salomon E. Über Faserstoffmangel im Blute bei einem Falle von Hämophilie. Dtsch Arch Klin Med: 1920; 132 240 244
21. World Federation of Hemophilia Report on the Annual Global Survey 2010. Montreal, Quebec, Canada: World Federation of Hemophilia. 2010 1-45. Available at: http://www1.wfh.org/publications/files/pdf-1427.pdf. Accessed June 27, 2013.
22. Lak M., Keihani M., Elahi F., Peyvandi F., Mannucci P. M. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol: 1999; 107 1 204 206
23. Peyvandi F., Mannucci P. M. Rare coagulation disorders. Thromb Haemost: 1999; 82 4 1207 1214
24. Mannucci P. M., Duga S., Peyvandi F. Recessively inherited coagulation disorders. Blood: 2004; 104 5 1243 1252
25. Viswabandya A., Baidya S., Nair S. C., et al. Correlating clinical manifestations with factor levels in rare bleeding disorders: a report from Southern India. Haemophilia: 2012; 18 3 e195 e200
26. Santacroce R., Cappucci F., Pisanelli D., et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis: 2006; 17 4 235 240
27. Acharya S. S., Coughlin A., Dimichele D. M. North American Rare Bleeding Disorder Study Group Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost: 2004; 2 2 248 256
28. Takezawa Y., Terasawa F., Matsuda K., et al. Molecular analysis of afibrinogenemic mutations caused by a homozygous FGA1238 bp deletion, and a compound heterozygous FGA1238 bp deletion and novel FGA c.54+3A>C substitution. Int J Hematol: 2012; 96 1 39 46
29. Peyvandi F., Haertel S., Knaub S., Mannucci P. M. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost: 2006; 4 7 1634 1637
30. Akcakus M., Patiroglu T., Keskin M., Koklu E., Gozukucuk A. Nonketotic hyperosmolar coma associated with splenic rupture in congenital afibrinogenemia. J Pediatr Hematol Oncol: 2004; 26 10 668 671
31. Peyvandi F., Kaufman R. J., Seligsohn U., et al. Rare bleeding disorders. Haemophilia: 2006; 12 03 137 142
32. Aubrey-Bassler F. K., Sowers N. 613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review. BMC Emerg Med: 2012; 12 1 11
33. Rodriguez-Merchan E. C. Surgical wound healing in bleeding disorders. Haemophilia: 2012; 18 4 487 490
34. James A. H. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia: 2005; 11 4 295 307
35. Peyvandi F., Bidlingmaier C., Garagiola I. Management of pregnancy and delivery in women with inherited bleeding disorders. Semin Fetal Neonatal Med: 2011; 16 6 311 317
36. Cetinkaya S. E., Pabuccu E. G., Ozmen B., Dokmeci F. Recurrent massive hemoperitoneum due to ovulation as a clinical sign in congenital afibrinogenemia. Acta Obstet Gynecol Scand: 2011; 90 2 192 194
37. Levrat E., Aboukhamis I., de Moerloose P., et al. A novel frameshift mutation in FGA (c.1846 del A) leading to congenital afibrinogenemia in a consanguineous Syrian family. Blood Coagul Fibrinolysis: 2011; 22 2 148 150
38. Suh T. T., Holmbäck K., Jensen N. J., et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev: 1995; 9 16 2020 2033
39. Iwaki T., Sandoval-Cooper M. J., Paiva M., Kobayashi T., Ploplis V. A., Castellino F. J. Fibrinogen stabilizes placental-maternal attachment during embryonic development in the mouse. Am J Pathol: 2002; 160 3 1021 1034
40. de Moerloose P., Boehlen F., Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost: 2010; 36 1 7 17
41. Grandone E., Tiscia G., Cappucci F., et al. Clinical histories and molecular characterization of two afibrinogenemic patients: insights into clinical management. Haemophilia: 2012; 18 1 e16 e18
42. Chevalier Y., Dargaud Y., Argaud L., Ninet J., Jouanneau E., Négrier C. Successive bleeding and thrombotic complications in a patient with afibrinogenemia: a case report. Thromb Res: 2011; 128 3 296 298
43. Ruiz-Sáez A. Thrombosis in rare bleeding disorders. Hematology: 2012; 17 01 S156 S158
44. De Marco L., Girolami A., Zimmerman T. S., Ruggeri Z. M. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest: 1986; 77 4 1272 1277
45. Korte W., Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Investig: 1994; 72 5 396 398
46. de Bosch N. B., Mosesson M. W., Ruiz-Sáez A., Echenagucia M., Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost: 2002; 88 2 253 258
47. Mosesson M. W., Antithrombin I. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost: 2003; 89 1 9 12
48. Ni H., Denis C. V., Subbarao S., et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest: 2000; 106 3 385 392
49. Remijn J. A., Wu Y. P., Ijsseldijk M. J., Zwaginga J. J., Sixma J. J., de Groot P. G. Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions. Thromb Haemost: 2001; 85 4 736 742
50. Risak E. Die fibrinogenie. Z Klin Med: 1935; 128 605
51. Peyvandi F., Palla R., Menegatti M., et al. European Network of Rare Bleeding Disorders Group Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost: 2012; 10 4 615 621
52. Kobayashi T., Kanayama N., Tokunaga N., Asahina T., Terao T. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol: 2000; 109 2 364 366
53. Hill M. B., Brennan S. O., Dear A., Strong J., Nejim T., Dolan G. Fibrinogen Nottingham II: a novel Bbeta Arg264gly substitution causing hypofibrinogenaemia. Thromb Haemost: 2006; 96 3 378 380
54. Dib N., Quelin F., Ternisien C., et al. Fibrinogen angers with a new deletion (gamma GVYYQ 346-350) causes hypofibrinogenemia with hepatic storage. J Thromb Haemost: 2007; 5 10 1999 2005
55. Brennan S. O., Davis R. L., Conard K., Savo A., Furuya K. N. Novel fibrinogen mutation γ314Thr→Pro (fibrinogen AI duPont) associated with hepatic fibrinogen storage disease and hypofibrinogenaemia. Liver Int: 2010; 30 10 1541 1547
56. Brennan S. O., Maghzal G., Shneider B. L., Gordon R., Magid M. S., George P. M. Novel fibrinogen gamma375 Arg->Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology: 2002; 36 3 652 658
57. Brennan S. O., Wyatt J., Medicina D., Callea F., George P. M. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly->Arg mutation. Am J Pathol: 2000; 157 1 189 196
58. Imperato C., Dettori A. G. [Congenital hypofibrinogenemia with fibrinoasthenia]. Helv Paediatr Acta: 1958; 13 4 380 399
59. Haverkate F., Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost: 1995; 73 1 151 161
60. Morris T. A., Marsh J. J., Chiles P. G., et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood: 2009; 114 9 1929 1936
61. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med: 2002; 126 11 1387 1390
62. Gillmore J. D., Lachmann H. J., Rowczenio D., et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol: 2009; 20 2 444 451
63. Tavares I., Lobato L., Moreira L., et al. Long-term follow-up of patients with hereditary fibrinogen A alpha-chain amyloidosis. Amyloid: 2011; 18 01 221 222
64. Pinney J. H., Lachmann H. J., Sattianayagam P. T., et al. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant: 2013; 13 2 433 441
65. Miesbach W., Scharrer I., Henschen A., Neerman-Arbez M., Spitzer S., Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis: 2010; 21 1 35 40
66. Dupuy E., Soria C., Molho P., et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res: 2001; 102 3 211 219
67. Colvin R. B., Mosesson M. W., Dvorak H. F. Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest: 1979; 63 6 1302 1306
68. Roberts H. R., Stinchcombe T. E., Gabriel D. A. The dysfibrinogenaemias. Br J Haematol: 2001; 114 2 249 257
69. Miesbach W., Schenk J., Alesci S., Lindhoff-Last E. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res: 2010; 126 6 e428 e433
70. Vu D., Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost: 2007; 5 01 125 131
71. Tirefort Y., Alson O. R., de Moerloose P., Neerman-Arbez M. Mutation of the translation initiation codon in FGA causes congenital afibrinogenemia. Blood Coagul Fibrinolysis: 2012; 23 6 556 558
72. Galanakis D. K., Neerman-Arbez M., Scheiner T., et al. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release. Blood Coagul Fibrinolysis: 2007; 18 8 731 737
73. Abdel Wahab M., de Moerloose P., Fish R. J., Neerman-Arbez M. Identification and functional characterization of a novel nonsense mutation in FGA accounting for congenital afibrinogenemia in six Egyptian patients. Blood Coagul Fibrinolysis: 2010; 21 2 164 167
74. Robert-Ebadi H., de Moerloose P., El Khorassani M., El Khattab M., Neerman-Arbez M. A novel frameshift mutation in FGA accounting for congenital afibrinogenemia predicted to encode an aberrant peptide terminating 158 amino acids downstream. Blood Coagul Fibrinolysis: 2009; 20 5 385 387
75. Hanss M., Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci: 2001; 936 89 90
76. Vorjohann S., Fish R. J., Biron-Andréani C., et al. Hypodysfibrinogenaemia due to production of mutant fibrinogen alpha-chains lacking fibrinopeptide A and polymerisation knob 'A'. Thromb Haemost: 2010; 104 5 990 997
77. Lefebvre P., Velasco P. T., Dear A., et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood: 2004; 103 7 2571 2576
78. Jayo A., Arnold E., González-Manchón C., Green D., Lord S. T. Hypodysfibrinogenemia causing mild bleeding and thrombotic complications in a compound heterozygote of AalphaIVS4+1G>T mutation and Aalpha4841delC truncation (Aalpha(Perth)). Thromb Haemost: 2009; 101 4 770 772
79. Meyer M., Dietzel H., Kaetzel R., Schmidt D., Liebscher K., Brennan S. O. Fibrinogen Leipzig II (gamma351Gly->Ser and gamma82Ala->Gly): hypodysfibrinogenaemia due to two independent amino acid substitutions within the same polypeptide chain. Thromb Haemost: 2007; 98 4 903 905
80. Ridgway H. J., Brennan S. O., Faed J. M., George P. M. Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol: 1997; 98 3 632 639
81. Koopman J., Haverkate F., Grimbergen J., Egbring R., Lord S. T. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA->stop TAA). Blood: 1992; 80 8 1972 1979
82. Ding Q., Ouyang Q., Xi X., Wang X., Shen Y., Wang H. Maternal chromosome 4 heterodisomy/isodisomy and Bβ chain Trp323X mutation resulting in severe hypodysfibrinogenaemia. Thromb Haemost: 2012; 108 4 654 661
83. Mc Donagh J. Dysfibrinogenemia and other disorders of fibrinogen structure or function. In: Colman R. W., Hirsh J., Marder V., Clowes A., George J., eds. Hemostasis and Thrombosis Basic Principles and Clinical Practice. 4th ed. Philadelphia, PA Lippincott Williams & Wilkins: 2001; 855 892
84. Siebenlist K. R., Mosesson M. W., Meh D. A., DiOrio J. P., Albrecht R. M., Olson J. D. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis: 2000; 11 3 293 304
85. Travlou A., Gialeraki A., Merkouri E., Politou M., Sfyridaki A., Neerman-Arbez M. Coexisting dysfibrinogenemia (gamma Arg275His) and FV Leiden associated with thrombosis (Fibrinogen Crete). Thromb Res: 2010; 126 2 e162 e164
86. Barrowcliffe T. W., Cattaneo M., Podda G. M., et al. New approaches for measuring coagulation. Haemophilia: 2006; 12 03 76 81
87. Kalina U., Stöhr H. A., Bickhard H., et al. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis: 2008; 19 8 777 783
88. Neerman-Arbez M., Vu D., Abu-Libdeh B., Bouchardy I., Morris M. A. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. Blood: 2003; 101 9 3492 3494
89. de Moerloose P., Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther: 2008; 8 7 979 992
90. Bolton-Maggs P. H., Perry D. J., Chalmers E. A., et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia: 2004; 10 5 593 628
91. De Vries A., Rosenberg T., Kochwa S., Boss J. H. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med: 1961; 30 486 494
92. Ra'anani P., Levi Y., Varon D., Gitel S., Martinowitz U. [Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen]. Harefuah: 1991; 121 9 291 293
93. Bornikova L., Peyvandi F., Allen G., Bernstein J., Manco-Johnson M. J. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost: 2011; 9 9 1687 1704
94. Schuepbach R. A., Meili E. O., Schneider E., Peter U., Bachli E. B. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia. Thromb Haemost: 2004; 91 5 1044 1046
95. Grech H., Majumdar G., Lawrie A. S., Savidge G. F. Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature. Br J Haematol: 1991; 78 4 571 572
96. Huq F. Y., Kadir R. A. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia: 2011; 17 01 20 30